Is early onset HER2-positive breast cancer associated with germline TP53 mutations?
This study suggests an association between germline TP53 mutations and early onset HER2-positive breast cancer. If confirmed in a larger cohort, these results could guide genetic testing strategies, lead to chemoprevention trials incorporating HER2-targeted therapies, and elucidate some of the molecular pathways involved in breast cancer.
The 3FSB had a great ability to find cancer in the gland, especially at the apex.